Following the paper by Asahara et al. 1 in 1997, research into the role of circulating endothelial progenitor cells in vascular regeneration and neovascularization has led to many novel insights into monocytemacrophage differentiation, the kinship between haematopoietic stem cells and angioblasts, and the role of innate immunity in vascular repair. It has gradually become acknowledged that the classically retrieved blood mononuclear fraction contains at least two flavours of circulating progenitor cells, the late outgrowth endothelial cells and the cells giving rise to endothelial cell colony-forming units (EC-CFUs). From the study by Padfield et al., 2 it is evident that the EC-CFU is a mixture of CD14 + /CD68 + myeloid cells and T-and B-lymphocytes rather than CD34 + cells and therefore do not represent an endothelial precursor cell per se. The observations do confirm the gain of endothelial marker expression of the CD14 + fraction, 3 but emphasize that this can reflect monocyte activation, rather than differentiation into endothelial cells. Besides the gain of endothelial markers, such as CD105, CD146, and Tie2, which are expressed by certain monocyte subtypes as well, a continuous expression of the leukocyte marker CD45 and an increase of the macrophage marker CD68 are seen. Moreover, when CD34 + cells are in vitro driven to express CD14, they also gain EC-CFU potential, illustrating the plasticity of the mononuclear cell fraction of blood. The study by Padfield and co-workers also shows that monocytes and macrophages in the CFU are proliferative. Long considered terminally differentiated, non-proliferative cells, monocytes and their macrophage counterparts can proliferate also when in a relevant environment as has recently been shown in atherosclerosis. 4 By thoroughly analysing the dynamics in the CFU, the CD14 + myeloid cells are found to be crucial. They secondarily lead to the attraction of CD3 + T-lymphocytes and CD19 + B-lymphocytes. The T-cells in CFUs derived from EC-CFUs were earlier described as CD3 + / CD31 + /CXCR4 + T-cells with high pro-angiogenic capacity. 5 Some of the features of EC CFUs are reminiscent of the described inflammatory events in vascular repair after injuries such as observed in percutaneous coronary intervention, transplant vasculopathy, and atherosclerosis. This suggested to the authors that the EC-CFU might be an in vitro correlate and perhaps a useful model or marker of local inflammation during vascular repair in vivo. They further suggest that EC-CFUs may be important in vascular repair by controlling local inflammation.
Indeed, the in vitro mechanisms in the CFU have also been established in neointima formation in vivo (Figure 1) T-lymphocytes and B-lymphocytes. 10 Monocytes are attracted to sites of injury by interaction with activated endothelium through increased expression of adhesion molecules, but also by tethering to activated platelets that cover the denuded injury site. Platelets subsequently activate monocytes, exemplified by the enhanced expression of VEGFR2.
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T-lymphocytes and B-lymphocytes serve primarily to limit neointima formation by inhibiting smooth muscle cell migration, a key mechanism in this process, 9,10 whereas natural killer T-lymphocytes are required for controlled neointima formation. 12 Although the in vivo conditions for these cells to function are obviously more complex than during in vitro CFU formation, the EC-CFU may serve as a model of local vascular inflammation (MOLVI). The phenotypic change of monocytes when in contact with activated platelets suggests that circulating and surveying monocytes become activated or at least modified at the site of injury rather than being recruited in activated state. 11 If true, the sought relationship between the level of circulating CD14 + monocytes and cardiovascular risk may not be as simple as desirable for a biomarker. In support of the hypothesis that a localized inflammation such as in vascular remodelling leads to a specialized activation of myeloid cells, Padfield et al. 13 in an earlier study induced systemic inflammation with a salmonella typhus vaccine and found no change in circulating numbers of EC-CFUs. Likewise, using a lipopolysaccharide challenge to achieve systemic inflammation, recruitment of CD14 monocytes into the blood stream as well as neointima formation in a simultaneously injured artery depended on the dose, 6 illustrating a complex relationship between circulating CD14 + monocytes and local vascular remodelling. In rheumatoid arthritis as an example of a chronic systemic inflammatory condition, CD14 + monocytes appear to be circulating in high numbers but dysfunctional in their capacity to induce neovascularization and vascular remodelling. will be required to define a meaningful biomarker of vascular remodelling and inflammation. If indeed the myeloid fraction becomes functionally activated at the site of injury, finding a circulating correlate that might serve as biomarker may even prove illusory. EC-CFUs may thus go through a career-switch from biomarker to a model of local vascular inflammation. 
